🔗 Share this article

While America proceeds with sweeping changes to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning COVID-19 vaccinations during the pandemic and has concentrated on potential deaths following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Agency leaders were set to reveal major revisions to the pediatric immunization program in December, bringing the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of step with much of the international standard with no evidence for improved outcomes. The planned update has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to head the division this year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific childhood immunization guidelines in the US to become more in line with the Danish model, a society with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Qualifications

Høeg has no apparent background in drug development, regulation or leadership, which has been customary for previous leaders of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a large organization. She is not an expert in industry regulation.”

Past commissioners of CBER would “grasp regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who ran the center have had.”

This division has an enormous portfolio at the FDA, Woodcock emphasized.

“Many people just zeroes in on the new drug program, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars division, OTC medication office and more, and each of these must be looked after,” she noted. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the job, which manages in excess of 5,000 employees. “It’s a enormous leadership role, if you do it right,” she added.

Official Statement and Disputed Policies

Regarding questions about Dr. Høeg's credentials and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a press secretary responded that the “concerns rely on flawed assumptions”.

“Her resume matches the responsibilities of her job,” the representative explained, pointing to the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a disputed expedited medication authorization process that allegedly concerned her preceding directors. “By what process are these medications being selected for this fast-track system? Who makes the calls?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, except for shots.”

Established Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, track record, Howard said. She published a study using unconfirmed crowd-sourced reports to estimate the frequency of heart inflammation after Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the current federal leadership featured changing guidelines for new vaccines and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has according to sources proposed barring adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and tailors the evidence to retrofit the science in a highly deceptive, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined other dissenters, {like|